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CARVEDILOL PROTECTS AGAINST APOPTOTIC CELL DEATH
INDUCED BY CISPLATIN IN RENAL TUBULAR EPITHELIAL CELLS
M. A. Carvalho Rodrigues1, G. Gobe2, N. A. G. Santos1, A. C. Santos1
1Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências
Farmacêuticas de Ribeirão Preto–USP, Ribeirão Preto, SP, Brasil
2Centre for Kidney Disease Research, School of Medicine, The University of Queensland at
Princess Alexandra Hospital, Brisbane, Queensland, Australia
Cisplatin is a highly effective chemotherapeutic drug; however, its use is limited by
nephrotoxicity. Studies showed that the renal injury produced by cisplatin involves oxida-
tive stress and cell death mediated by apoptosis and necrosis in proximal tubular cells.
The use of antioxidants to decrease cisplatin-induced renal cell death was suggested as a
potential therapeutic measure. In this study the possible protective effects of carvedilol, a
beta blocker with antioxidant activity, was examined against cisplatin-induced apoptosis in
HK-2 human kidney proximal tubular cells. The mitochondrial events involved in this protec-
tion were also investigated. Four groups were used: controls (C), cisplatin alone at 25 µM
(CIS), cisplatin 25 µM plus carvedilol 50 µM (CV + CIS), and carvedilol alone 50 µM (CV).
Cell viability, apoptosis, caspase-9, and caspase-3 were determined. Data demonstrated that
carvedilol effectively increased cell viability and minimized caspase activation and apoptosis
in HK-2 cells, indicating this may be a promising drug to reduce nephrotoxicity induced by
cisplatin.
Cisplatin (cisplatinum, cis-diamminedichlo
roplatinum-II) is an important chemotherapeu-
tic drug that has been largely used in treatment
of solid and hematological tumors (Shermann
and Lippard 1987). Currently, cisplatin remains
one of the most effective chemotherapeutic
agents and is used in the management of a
variety of tumors, including testicular, ovarian
epithelial and germ cell, head and neck, blad-
der, endometrial, cervical, non-small-lung cell,
malignant melanoma, penile, and adrenocorti-
col carcinoma. The use of cisplatin in testicular
cancer increased the cure rates from 20 to
95% (Wang and Lippard 2005). The therapeu-
tic activity is dose dependent, and achievement
of full therapeutic potential is limited mainly by
nephrotoxicity (Cvitkovic 1998; Hanigan and
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Devarajan 2003). For this reason, nephrotox-
icity induced by cisplatin and the pathways
related to this toxicity have been the targets of
many research groups globally.
Approximately 20% of patients receiving
high doses of cisplatin develop severe renal
dysfunction (Yao et al. 2007). The kidney not
only is responsible for cisplatin excretion, but
also is the site of accumulation of this drug
(Schenellmann 2001). The cisplatin concen-
trations in renal tubular epithelium cells are
fivefold higher than serum, and the S3 segment
of renal proximal tubule accumulates the high-
est concentration of drug (Kroning et al. 2000;
Yao et al. 2007).
Cisplatin-mediated nephrotoxicity is rec-
ognized as a complex, multifactorial process.
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In vitro assays suggest that high doses of
cisplatin induce necrosis, while lower doses
induce apoptosis. Lieberthal et al. (1996)
demonstrated that high concentrations of
cisplatin (200 to 800 μM) induced necrosis
in primary cultures of mouse proximal tubu-
lar cells, while lower concentrations (2 to
8 μM) resulted in apoptosis. Baek et al. (2003)
reported that cisplatin induced necrosis at
2 mM but apoptosis at 50 μM in renal proximal
tubular epithelial cells. Similarly, both necrosis
and apoptosis seem to be induced in vivo and
their occurrence depends on dosage. Extensive
injury leads to necrotic cell death, but thera-
peutic doses produce less severe renal injury,
which is associated mainly with apoptosis of
renal tubular epithelial cells (Hanigan and
Devarajan 2003; Lau 1999; Lieberthal et al.
1998; Ramesh and Reeves 2003; Ueda et al.
2000).
Oxidative stress and inflammation were
suggested as important mechanisms in the
pathogenesis of cisplatin-induced nephrotoxic-
ity (Ali and Al Moundhri 2006; Pabla and Dong
2008; Yao et al. 2007). Oxidative stress is rec-
ognized as an important factor, which induces
apoptosis in various types of cells (Megyesi et al.
1998; Mukhopadhyay et al. 2011). Cisplatin
disrupts the mitochondrial respiratory chain,
producing excess of reactive oxygen species
(ROS), mainly the superoxide radical, a pre-
cursor of hydrogen peroxide and hydroxyl
radicals (Kruidering et al. 1997; Turrens
2003).
Generation of ROS is an early signal respon-
sible for the activation of death signalling path-
ways (Pabla and Dong 2008). Kruidering and
colleagues (1997) indicated that complexes I
to IV of the respiratory chain are inhibited
in cells after treatment with cisplatin, which
is an important source of ROS. In response
to mitochondrial damage induced by cisplatin,
cytochrome c is released into the cytosol and
becomes part of a complex with apoptotic
peptidase activating factor-1 (Apaf-1) and
caspase-9. The activation of caspase-9 leads
to downstream activation of other caspases,
such as caspase-3, culminating in cell death by
apoptosis (Cullen et al. 2007).
The use of antioxidants as a strategy against
nephrotoxicity induced by cisplatin was sug-
gested as follows: vitamin C (Tarladacalisir et al.
2008), vitamin E (Ajith et al. 2009), resveratrol
(Do Amaral et al. 2008), quercetin (Francescato
et al. 2004), dimethylthiourea (Santos et al.
2008), and N-acetylcysteine (Dickey et al.
2005).
Carvedilol is a third-generation, vasodi-
lating non-cardioselective beta(β)-adrenergic
receptor antagonist, which lacks intrinsic sym-
pathomimetic activity (Stafylas and Sarafidis
2008). Carvedilol is used to treat conges-
tive heart failure, mild to moderate hyperten-
sion, and myocardial infarction (Feuerstein and
Ruffolo 1995; Watanabe et al. 2000). Beyond
its action as β-blocker, this drug presents
other properties, such as antioxidant, calcium
antagonist, antiinflammatory, immunomodu-
latory and antifibrotic activities (Pauschinger
et al. 2005; Stafylas and Sarafidis 2008). The
potent antioxidant activity of carvedilol may
be attributed to a distinctive characteristic not
present in other drugs from the same phar-
macological class (β-blockers), which seems
to be the presence of a carbazole moiety
in the molecule (Kramer and Weglicki 1996;
Rodrigues et al. 2011).
Two main mechanisms are possibly
involved in this property: scavenging free
radicals; or sequestering ferric ion, thereby
avoiding the Fenton reaction (Noguchi et al.
2000). Recently, Rodrigues et al. (2010;
2011) showed that carvedilol was able to
preserve renal function of rats treated with
cisplatin by maintenance of mitochondrial
function and prevention of oxidative stress.
The aim of the current study was to investigate
the mechanisms underlying carvedilol’s ability
to protect against cisplatin-induced cell death
in renal proximal tubular epithelial cells.
MATERIAL AND METHODS
Materials
Cell culture media were purchased from
Sigma-Aldrich Pty Ltd (Castle Hill, Australia),
fetal bovine serum (FBS) was from Bovogen
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Biologicals Pty Ltd (East Keilor, Australia),
bovine serum albumin (BSA) was from GIBCO
(Mulgrave, Australia), and antibiotics mix
including penicillin and streptomycin was from
Invitrogen (Mulgrave, Australia). All chemicals
were of the highest grade and obtained from
Sigma-Aldrich Pty Ltd (Castle Hill, Australia).
The protein assay kit was purchased from
Bio-Rad Pty Ltd (Regents Park, Australia).
Caspase-3 antibody was from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA; sc- 7148),
and the antibody for caspase-9 was from Cell
Signaling Technology (Beverley, MA; number
9661).
Cell Culture
The human renal proximal tubular
epithelial cells (HK-2) were obtained from the
American Type Culture Collection (Rockville,
MD). Although HK-2 cells comprise an immor-
talized cell line and therefore may have
some characteristics of cancer cells, they have
been accepted in numerous publications as
a model for normal renal tubular epithelium
(Davidson et al. 2005). Cells were maintained
in Dulbecco’s modified Eagle’s medium/Ham’s
F-12 with antibiotics (penicillin at 1000 U/ml
and streptomycin at 1000 μg/ml) and 10%
FBS, and incubated at 37◦C in 5% CO2 in air at
high humidity. The medium was changed every
3–4. Cells were used for assays after reaching
80–90% confluency.
Cell Treatment
Cells were prepared for treatments in
12-well plates on 12-mm-diameter glass cover-
slips or in 10-cm petri dishes for protein extrac-
tion and Western blot analysis. Cisplatin stock
solution (2 mM) was prepared in phosphate
buffered saline (PBS) and carvedilol stock solu-
tion (12.3 mM) was prepared in dimethyl sul-
foxide (DMSO). Cells were divided in 4 groups:
I, control (C); II, cisplatin alone at 25 μM
(CIS); III, carvedilol + cisplatin (CV + CIS); IV,
carvedilol alone at 50 μM (CV). Fresh stock
solutions were prepared for each treatment.
Treatments were started 24 h after cells were
plated. An initial concentration response using
12.5, 25, 50, or 100 μM of cisplatin and 5, 25,
or 50 μM of carvedilol was used to select final
treatment concentrations (data not shown); the
concentrations selected were 25 μM cisplatin
and 50 μM carvedilol. Note that at 25 μM
cisplatin, no necrosis was seen in any of the fol-
lowing treatments, and only assays for apoptosis
are described. Treatments lasted 24 h. Control
groups had fresh medium replaced at the start
of the treatments. The vehicles for cisplatin
(PBS) and carvedilol (DMSO) were added to
controls in the same amount as for treated
groups. For the treatments where serum-free
medium was used, the FBS was replaced by
0.5% BSA. Experiments were performed in trip-
licate.
Trypan Blue Assay
For trypan blue assay, cells grown in 12-well
plates were treated, then trypsinized after 24 h,
and spun at 349 × g for 5 min at 4◦C.
The pellet was suspended in 200 μl ster-
ile PBS, and then 50 μl cell suspension was
mixed with 50 μl of 0.4% trypan blue and
counted using a hemacytometer. Stained non-
viable (blue) and viable (nonstained) cells were
counted under light microscopy at 40× mag-
nification (Olympus BH2 light microscope with
optical grid). Results were expressed as percent
total number of cells.
Analysis of Apoptosis
After the 24-h treatment, glass coverslip cul-
tures were washed with PBS and then fixed
in 10% buffered formalin. Fixed coverslip cul-
tures were stained routinely using hematoxylin
and eosin (H&E). To quantify apoptosis, sec-
tions were examined at 400× magnification,
and apoptotic and normal cells were counted
in at least 10 fields per coverslip. Apoptosis was
assessed as shrunken, darkly staining cells with
condensed, marginated nuclear chromatin and
intact cell membranes; discrete apoptotic bod-
ies comprising large dense, pyknotic, nuclear
fragments usually surrounded by a narrow
cytoplasm; and clusters of small apoptotic
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bodies that appeared to originate from one cell.
Counts of apoptosis were calculated as per-
cent total cells in the microscopic field of view
(Davidson et al. 2005).
Protein Extraction and Western
Immunoblot
Supernatant from cell cultures was spun
at 349 × g for 5 min. The pellet was
collected and added to cells scraped from
the petri dish surface using RIPA cell lysis
buffer (150 mM NaCl, 24 mM NaF, 0.5 mM
ethylenediamine tetraacetic acid [EDTA], 0.1%
sodium dodecyl sulfate [SDS], 1% IGEPAL CA-
630, 50 mM Tris-HCl, pH 7.5). Cells were
then disrupted using a sonicator and spun
at 16,000 × g for 20 min at 4◦C. The
supernatant was collected and protein content
measured using the Pierce bicinchoninic (BCA)
protein assay kit (Thermo, Rockford, IL). Lysates
were aliquoted and stored at –80◦C until use.
Equal amounts of protein, containing 20 μg,
were resolved in 8–10% sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to a polyvinylidene difloride
(PVDF) membrane, and blocked for nonspe-
cific antibody binding using 5% nonfat milk
powder in PBS solution with 0.05% Tween-
20 (PBST). After the blocking step, mem-
branes were blotted with primary antibodies
diluted 1:1000 for caspase-9 and 1:700 for
caspase-3 in 1% nonfat milk powder in PBST
overnight at 4◦C. Membranes were then sub-
mitted to secondary goat anti-rabbit antibody
diluted 1:5000 for capase-9 and 1:7000 for
caspase-3. Presence and expression levels
of the proteins of interest were determined
using SuperSignal West Pico Chemiluminescent
Substrate (Pierce, Rockford, IL). After mea-
sured densitometry of bands, antibodies were
removed from the membrane using stripping
buffer (100 mM β-mercaptoethanol, 2% SDS,
62.5 mM Tris-HCl, pH 6.8), and the process
of immunoblotting was repeated using GAPDH
(1:20,000) as primary antibody to verify equal
loading of protein in each lane. The ratios
between the protein of interest and GAPDH
were calculated from densitometry, and the dif-
ference in intensity of the signals was analyzed
by Scion Image software (Scion Corporation,
Frederick, MD) (Morais et al. 2006).
Statistics
Results were expressed as mean ± SEM.
Analysis of variance (ANOVA) with Bonferroni’s
multiple comparison was used to determine
significance of differences between controls
and treatments, and p < .05 was consid-
ered to be significant. Analyses were per-
formed using Graphpad Prism software 5.0
(San Diego, CA).
RESULTS
Cellular Viability (Trypan Blue Assay)
The control group displayed 92% viability,
similar to the CV group. The treatment with
cisplatin significantly decreased cellular viability
approximately 20% compared to control. In the
group treated with cisplatin plus carvedilol, cel-
lular viability was significantly increased com-
pared with cisplatin alone (Figure 1).
Apoptosis
HK-2 cells treated with cisplatin had sig-
nificantly increased apoptosis compared to
controls with no associated necrosis. The addi-
tion of carvedilol markedly decreased apoptosis
FIGURE 1. Percentage of cell viability of HK-2 cells measured by
trypan blue assay after each treatment is demonstrated. Values
are expressed as the mean ± SEM. Asterisk indicates significantly
different compared with C (p < .05); #, significantly different
compared with CIS (p < .05).
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FIGURE 2. Percentage of apoptosis in HK-2 cells stained with
hematoxylin and eosin and counted under light microscopy
(×40) is demonstrated for each treatment. Values are expressed
as mean ± SEM. Asterisk indicates significantly different com-
pared with C (p < .05); #, significantly different compared with
CIS (p < .05).
compared to cisplatin, indicating an effective
protection. No marked difference between CV
and control was observed (Figure 2).
Protein Analysis of Caspase-9 and
Caspase-3 (Western Immunoblot)
For measuring caspase-3 and caspase-9
expression and activity, the densitometry ratios
of the bands from caspase-3 and caspase-9
were compared to GAPDH. Pro caspase-3
(32 kD) densitometry increased in the CIS
group compared to controls, while compari-
son between other groups did not show any
difference. For cleaved caspase-3, the subunit
corresponding to 21 kD was analyzed. Results
showed significant cleavage of caspase-3 for the
CIS compared to controls. The CV + CIS group
was similar to controls and significantly lower
than CIS alone, indicating that carvedilol was
able to avoid activation of caspase-3 (Figure 3).
For caspase-9, densitometry of pro-
caspase-9 (45 kD) and the subunit at 35 kD
for cleaved caspase-9 were used. The pro-
caspase-9 ratio was increased in the group
treated with cisplatin compared to controls and
CV + CIS. However, no marked difference was
noted between groups for cleaved caspase-9
(Figure 4).
DISCUSSION
Trying new approaches to avoid cisplatin
nephrotoxicity is a field of interest for many
scientists globally. Amifostine (Ethiol), a broad-
spectrum cytoprotector, is the only accepted
treatment for minimizing the toxicity of
cisplatin approved by the U.S. Food and
Drug Administration (FDA). However, studies
showed that amifostine is not always able to
protect noncancer cells. For example, it was not
able to protect against ototoxicity induced by
cisplatin combined with etoposide and bleomi-
cyn in the treatment of pediatric germ-cell
tumors (Ali and Al Moundhri 2006; Marina
et al. 2005). Further, Sastry and Kellie (2005)
reported a case of a girl, treated for ovarian car-
cinoma with cisplatin, who developed severe
neurotoxicity, ototoxicity, and nephrotoxicity
despite the use of amifostine.
The use of antioxidants in order to ame-
liorate cisplatin-induced toxicity has been
exploited after some studies showed that oxida-
tive stress played an important role in cell death
induced by cisplatin (Baliga et al. 1999; Santos
et al. 2007). Successful cytoprotective results
were noted in vitro and in animal models with
the use of antioxidants N-acetylcysteine, glu-
tathione, dimethylthiourea, lycopene, vitamins
C and E, glutamine, capsaicin, quercetin, and
others, but these rarely reached human trials
(Pabla and Dong 2008).
The ability of cisplatin to induce cell death,
including apoptosis, in renal tubular epithelial
cells is well established (Lieberthal et al. 1996).
However, carvedilol-mediated protection
against cell death and apoptosis induced by
cisplatin has not been described previously in
any in vitro model. Previously Rodrigues et al.
(2010; 2011) demonstrated that carvedilol
was able to prevent mitochondrial impair-
ment, oxidative stress, and the activation
of caspase-3 in kidneys of rats treated with
cisplatin. In the present study, HK-2 cells were
used to investigate the levels of apoptosis,
particularly the involvement of the intrinsic
apoptotic pathway in the protective action of
carvedilol. The caspase family plays a central
role in apoptotic cell death. These proteins
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p21p32
A
B
GAPDH
GAPDH
C CIS CV+CIS CV
C CIS CV+CIS CV
C
D
FIGURE 3. Procaspase-3 immunoblot (p32) bands and GAPDH (36KDa) for groups C, CIS, CV + CIS, and CV are shown (A). Ratio for
densitometry calculated for these bands is demonstrated in (B). Cleaved caspase-3 immunoblot (p21) bands and GAPDH (36 kD) for
groups C, CIS, CV + CIS, and CV are also shown (C). Ratio for densitometry calculated for these bands is demonstrated in (D). Values are
expressed as mean ± SEM. Asterisk indicates significantly different compared with C (p < .05); #, significantly different compared with
CIS (p < .05).
p35p45
CA
GAPDH
GAPDH
CVCV+CISCISC
C CIS CV+CIS CV
B D
FIGURE 4. Procaspase-9 immunoblot (p45) bands and GAPDH (36 kD) for groups C, CIS, CV + CIS, and CV are shown (A). Ratio for
densitometry calculated for these bands is demonstrated in (B). Cleaved caspase-9 immunoblot (p35) bands and GAPDH (36 kD) for
groups C, CIS, CV + CIS, and CV are also shown (C). Ratio for densitometry calculated for these bands is demonstrated in (D). Values are
expressed as mean ± SEM. Asterisk indicates significantly different compared with C (p < .05); #, significantly different compared with
CIS (p < .05).
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are cysteine proteases that exist as latent
zymogens. In response to apoptotic stimuli,
caspases are activated and the pro-enzyme
is proteolitically cleaved to smaller subunits,
generally approximately 10 to 20 kD in size.
Using specific antibodies, it is possible to detect
and measure caspases by Western immunoblot
assays (Wolf and Green 1999). To explain how
apoptosis was induced and how carvedilol
acted as protector, caspase-9 and caspase-3
were measured by Western immunoblot
analysis.
Caspase-9 is the initiator caspase of the
mitochondrial, or intrinsic, pathway that is
engaged in many apoptotic stimuli. After a
situation of oxidative stress, cytochrome c is
released from mitochondria into the cytosol
and activates Apaf-1. Apaf-1 binds to caspase-
9 activating a multimeric complex, the apopto-
some. Once activated, caspase-9 cleaves and
activates the downstream effector caspase-3
(Allan and Clarke 2009).
Caspase-3 activation is the final step in the
caspase cascade, prior to the structural disinte-
gration of the cell in apoptosis. After caspase-3
is activated, a wide variety of physiological
substrates are cleaved, including DNA repair
enzymes, ICAD (inhibitor of caspase-activated
DNase) or DNA fragmentation factor, nuclear
structural proteins, and cytoskeleton proteins
(Kaushal et al. 2001).
In our study, carvedilol was able to pro-
tect against the increase of pro-caspase-9,
caspase-3 activation, and cellular death
induced by cisplatin, which is in agreement
with our previous findings (Rodrigues et al.
2011). Interestingly, differences in expression of
cleaved caspase-9 were not found among the
groups. The treatment duration may be a basis
for a lack of observed difference. The increase
in cleaved caspase-9 may occur some hours
after the cisplatin-induced rise in pro-caspase-
9, and during this interval caspase-3 may be
activated by nonmitochondrial pathways or
even by pro-caspase-9 itself. In agreement
with our hypothesis, Stennicke et al. (1999)
investigated whether cleavage of caspase-9 was
necessary or whether pro-caspase-9 must
remain attached to Apaf-1 to retain activity.
Results showed that pro-caspase-9 itself has
significant activity in the presence of cytosolic
factors such as Apaf-1, which implies that
proteolysis of caspase-9 does not seem to
be a requirement for activation. Binding to
cytosolic factors enhances pro-caspase-9 activ-
ity 2000-fold, which is sufficient to activate
procasp-3 in a few minutes (Stennicke et al.
1999). More recently, Bratton and Salvesen
(2010) found that pro-caspase-9 had a higher
affinity for the apoptosome than the cleaved
caspase-9, facilitating a continuous cycle of
pro-caspase-9 recruitment and activation,
processing, and release from the complex.
Kaushal et al. (2001) found that treatment
of LLC-PK1 kidney tubular epithelial cells with
50 μM cisplatin elevated activity of caspase-3 at
approximately 12 h posttreatment, continuing
to increase up to 30 h. For caspase-9, the
enhanced activity occurred to a lesser degree,
starting after activation of caspase-3 was initi-
ated. Data suggested that activation of caspase-
9 needs to precede caspase-3 and that another
pathway may contribute to caspase-3 activation
(Kaushal et al. 2001).
In summary, our results are the first obser-
vation describing the effects of carvedilol as a
protective agent against toxicity and cell death
induced by cisplatin in renal tubular epithelial
cells. Taken together, our previous (Rodrigues
et al. 2010; 2011) and present findings indicate
that the protective mechanisms of carvedilol
may involve antioxidant properties, protection
of the mitochondria, and inhibition of expres-
sion and/or activity of caspase-9; however,
further studies are needed. The impact of
carvedilol on other death pathways activated
by cisplatin, such as the extrinsic (death recep-
tors, caspase-8) and endoplasmic reticulum
(caspase-12) pathways, also need to be inves-
tigated. Nevertheless, carvedilol is a widely
employed drug, well tolerated by patients, and
able to protect against the cell death induced
by cisplatin in renal tubular cells, which are
important characteristics for future use of this
drug in human trials of renoprotection from
cisplatin-induced toxicity.
There is a concern that antioxidants might
interfere in the antitumor activity of cisplatin.
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However, the nephrotoxic and the antitu-
mor mechanisms due to cisplatin may not be
similar. The dividing tumor cells are partic-
ularly susceptible to the genotoxic effect of
cisplatin, while the adverse effects on kid-
neys are associated with oxidative damage and
inflammatory events (Eastman 1999; Hanigan
and Devarajan 2003). The increased genera-
tion of ROS induced by cisplatin might not
play a key role in the antineoplastic activ-
ity of cisplatin as opposed to nephrotoxicity
(Matsushima et al. 1998; Santos et al. 2008;
Somani et al. 2000; Wang and Lippard 2005).
In this context carvedilol might be an interesting
alternative for use in nephroprotection.
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